Toxicity of a combination of ABVD chemotherapy and mediastinal irradiation for Hodgkin's disease patients with massive initial mediastinal involvement.
Toxicity of a combination of ABVD chemotherapy and mediastinal irradiation for Hodgkin's disease patients with massive initial mediastinal involvement.
复制标题
ABVD 化疗和纵隔放疗组合对初始大量纵隔受累的霍奇金病患者的毒性。
作者：
J. Lagrange;A. Thyss;C. Caldani;M. Héry;M. Schneider;J. Bensadoun
作者报告了 5 例纵隔胸比大于或等于 0.35 的霍奇金病 (HD) 患者，他们接受 ABVD 化疗（阿霉素、博莱霉素、长春地辛、DTIC）和放疗。 5名患者全部出现并发症，其中1人死亡。阿霉素和博莱霉素联合放射治疗可能是造成治疗耐受性差的原因。在治疗大面积纵隔受累的患者时，应避免使用此类方案，尤其是纵隔照射后使用 ABVD。
The authors report on 5 Hodgkin's disease (HD) patients with a mediastinothoracic ratio greater than or equal to 0.35 treated by ABVD chemotherapy (adriamycin, bleomycin, vindesine, DTIC) and irradiation. All 5 patients developed complications and there was 1 death. Administration of adriamycin and bleomycin in combination with irradiation may have been responsible for this poor treatment tolerance. Use of such protocols, and especially use of ABVD after mediastinal irradiation, should probably be avoided in the management of patients with massive mediastinal involvement.